Can loratadine help in treating granulocyte-colony stimulating factor-induced bone pain?

Shilpa N Gajarawala1, Jessica N Pelkowski, Christopher C DeStephano

  • 1Shilpa N. Gajarawala practices in the Department of Medical and Surgical Gynecology at Mayo Clinic Florida, is an assistant professor in obstetrics and gynecology in the Mayo Clinic College of Medicine, and is an adjunct faculty member for the DMSc program at Rocky Mountain University of Health Science in Provo, Utah. Jessica N. Pelkowski is an NP in the Department of Orthopedic Surgery at Mayo Clinic Florida, and an assistant professor of orthopedic surgery and instructor of nursing in the Mayo Clinic College of Medicine. Christopher C. DeStephano practices in the Department of Medical and Surgical Gynecology at Mayo Clinic Florida and is an assistant professor of obstetrics and gynecology in the Mayo Clinic College of Medicine. The authors have disclosed no potential conflicts of interest, financial or otherwise.

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
1.4K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
411
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
299